Table 2.
Clinical Characteristics of Pediatric Patients with Inflammatory Bowel Disease in the DYNAMIC Cohort
Diagnosis, n (%) | |
Crohn’s disease | 55 (79.71) |
Ulcerative colitis | 8 (11.59) |
IBD-U | 6 (8.70) |
Median age at diagnosis, y (range) | 12.97 (7.52–17.74) |
Years since diagnosis at enrollment, median (range) | 0.02 (0.00–9.66) |
Crohn’s disease–Paris Classification lower GI tract location, n (%) | |
Ileal L1 | 12 (22.64) |
Colonic L2 | 9 (16.98) |
IIeocolonic L3 | 30 (56.60) |
None | 2 (3.77) |
Crohn’s disease–Paris Classification phenotype, n (%) | |
Inflammatory B1 | 48 (87.27) |
Stricturing B2 | 5 (9.09) |
Stricturing/penetrating B2/B3 | 2 (3.64) |
Ulcerative colitis extent/IBD-U, n (%) | |
E2 left-sided colitis | 5 (41.67) |
E4 pancolitis | 7 (58.33) |
Patients initiating therapy at enrollment, n (%) | 31 (44.93) |
Current medication for IBD, n (%) | |
Mesalamine | 26 (37.68) |
Biologic | 44 (63.77) |
Steroids | 8 (11.59) |
Immunomodulators | 15 (21.74) |
Calprotectin level, ug/dL, median (IQR) | |
Baseline | 689 (180–1702.5) |
Week 4 | 421 (94–998) |
Week 8 | 300 (48–809) |
Disease activity index, median (range) | |
Pediatric Crohn’s Disease Activity Index | |
Baseline | 30 (0–50) |
Week 4 | 7.5 (0–37.5) |
Week 8 | 7.5 (0–55) |
Pediatric Ulcerative Colitis Activity Index | |
Baseline | 45 (0–75) |
Week 4 | 10 (0–40) |
Week 8 | 10 (0–45) |
GI, gastrointestinal; IQR, interquartile range.